In PCa, an elevated level of VTCN1 is associated with activation of genes that establish cancer stem cells (CSC), pathological high tumour stage and poor or shorter OS rate, making it a potential independent prognostic biomarker and therapeutic target [149,150]. The gene discussed is VTCN1; the disease is posterior cortical atrophy.